TY - JOUR
AR - CJSO-2020-1-101
TI - Antitumor Effects of RHAMM-Target Peptides on Prostate Tumor Xenografts in Nude Mice
AU - Natalia , Akentieva
JO - Chinese Journal of Surgical Oncology
PY - 2020
DA - Wed 17, Jun 2020
SN - 
DO - http://dx.doi.org/10.31487/j.CJSO.2020.01.01
UR - https://www.sciencerepository.org/antitumor-effects-of-rhamm-target-peptides-on-prostate-tumor-xenografts_CJSO-2020-1-101 
KW - RHAMM, peptides, tumor, mice xenografts
AB - Prostate cancer is a high incidence disease in men and a major cause of cancer deaths. RHAMM-target
peptides used for treatments of prostate tumors. Peptides were added to the PC3mLN4 cells (GEGEEGEE,
DFGEEAEE and RYQLHPYR, final concentration 40 μg / ml, dose for inoculating the mouse 2.5 mg / kg).
45 nude mice were injected with 0.1 ml of PC3mLN4 cell suspension of 2 × 107
cells/ml subcutaneously.
The nude mice models were randomly divided into five groups of 8 in each group. The standard models in
mice were judged by 100% tumor grafting. The results showed that GEGEEGEE peptide inhibited tumor
growth by 58%, DFGEEAEE peptide inhibited tumor growth by 63.5%, but RYQLHPYR peptide
significantly inhibited of tumor growth by 94.6%. These results have demonstrated that RHAMM-target
peptides have a therapeutic potential for the treatment of cancer.